Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Cirtuvivint (Primary) ; Irinotecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SLICK Trial
Most Recent Events
- 22 Dec 2025 Status changed from not yet recruiting to recruiting.
- 15 Sep 2025 New trial record